Literature DB >> 15327028

Human herpesvirus 6 infects the central nervous system of multiple sclerosis patients in the early stages of the disease.

A Rotola1, I Merlotti, L Caniatti, E Caselli, E Granieri, M R Tola, D Di Luca, E Cassai.   

Abstract

The presence and the replicative state of human herpesvirus 6 (HHV-6) were evaluated in clinical samples from multiple sclerosis (MS) patients at the first time of MS diagnosis. HHV-6 variant B was present in peripheral blood mononuclear cells of 5/32 (15%) patients, but persisted with a latent infection. Viral sequences were present also in cerebrospinal fluid (CSF), both free in the liquid (7/32, 22%) and latent in the cellular fraction (3/32, 9%), as shown by analysis of viral transcription. In these cases, variant A was detected. HHV-6 DNA sequences present in the CSF were associated to mature viral particles. In fact, in vitro infectious assays of CSF showed the presence of replication-competent virions. These results show that about 20% of MS patients have active foci of HHV-6 variant A infection in the early stages of the disease and suggest that viral replication takes place within the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15327028     DOI: 10.1191/1352458504ms1045oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  21 in total

Review 1.  Human herpesvirus 6 infection as a trigger of multiple sclerosis.

Authors:  Konstantine I Voumvourakis; Dimitrios K Kitsos; Sotirios Tsiodras; George Petrikkos; Eleftherios Stamboulis
Journal:  Mayo Clin Proc       Date:  2010-10-06       Impact factor: 7.616

2.  Development of a human herpesvirus 6 species-specific immunoblotting assay.

Authors:  Yuki Higashimoto; Akane Ohta; Yukihiro Nishiyama; Masaru Ihira; Ken Sugata; Yoshizo Asano; Daniel L Peterson; Dharam V Ablashi; Paolo Lusso; Tetsushi Yoshikawa
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

3.  Altered innate immune response of plasmacytoid dendritic cells in multiple sclerosis.

Authors:  A Bayas; M Stasiolek; N Kruse; K V Toyka; K Selmaj; R Gold
Journal:  Clin Exp Immunol       Date:  2009-09       Impact factor: 4.330

4.  Presumptive human herpesvirus 6 myelopathy in an immunocompetent patient.

Authors:  Roger E Kelley; Joseph R Berger; Mary Espey; Brian P Kelley
Journal:  J Neurovirol       Date:  2014-11-04       Impact factor: 2.643

Review 5.  Chemokines encoded by herpesviruses.

Authors:  Sergio M Pontejo; Philip M Murphy
Journal:  J Leukoc Biol       Date:  2017-08-28       Impact factor: 4.962

6.  Prevalence of human Herpesviridae in cerebrospinal fluid of patients with multiple sclerosis and noninfectious neurological disease in the Netherlands.

Authors:  Gijsbert P van Nierop; Rogier Q Hintzen; Georges M G M Verjans
Journal:  J Neurovirol       Date:  2014-03-27       Impact factor: 2.643

Review 7.  The molecular biology of human herpesvirus-6 latency and telomere integration.

Authors:  Jesse H Arbuckle; Peter G Medveczky
Journal:  Microbes Infect       Date:  2011-03-31       Impact factor: 2.700

Review 8.  Classification of HHV-6A and HHV-6B as distinct viruses.

Authors:  Dharam Ablashi; Henri Agut; Roberto Alvarez-Lafuente; Duncan A Clark; Stephen Dewhurst; Dario DiLuca; Louis Flamand; Niza Frenkel; Robert Gallo; Ursula A Gompels; Per Höllsberg; Steven Jacobson; Mario Luppi; Paolo Lusso; Mauro Malnati; Peter Medveczky; Yasuko Mori; Philip E Pellett; Joshua C Pritchett; Koichi Yamanishi; Tetsushi Yoshikawa
Journal:  Arch Virol       Date:  2013-11-06       Impact factor: 2.574

9.  Human herpesvirus 6A (HHV-6A) and HHV-6B alter E2F1/Rb pathways and E2F1 localization and cause cell cycle arrest in infected T cells.

Authors:  Guy Mlechkovich; Niza Frenkel
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

10.  Immunomodulation and immunosuppression by human herpesvirus 6A and 6B.

Authors:  Lorenzo Dagna; Joshua C Pritchett; Paolo Lusso
Journal:  Future Virol       Date:  2013-03       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.